Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Neurology

• Publication date

  2013-02-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s00415-012-6663-7PMID 23001556
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cognitive Dysfunction in Multiple Sclerosis

  2012cited by this paper
• Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

  2012cited by this paper
• Evaluating cognitive outcome measures for MS clinical trials: what is a clinically meaningful change?

  2012cited by this paper
• Methylphenidate for fatigue in ambulatory men with prostate cancer

  2010cited by this paper
• Fatigue and stimulant use in military fighter aircrew during combat operations.

  2010cited by this paper
• Use of an acute challenge with d‐amphetamine to model cognitive improvement in chronic schizophrenia

  2010cited by this paper
• Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

  2010cited by this paper
• Pharmacological treatments for fatigue associated with palliative care.

  2010cited by this paper
• Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test

  2010cited by this paper
• Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis

  2009cited by this paper
• Methamphetamine self-administration by humans subjected to abrupt shift and sleep schedule changes

  2009cited by this paper
• Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study

  2008cited by this paper
• Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire

  2008cited by this paper
• Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue.

  2008cited by this paper
• New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD.

  2008cited by this paper
• Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults.

  2007cited by this paper
• Reliability and validity of neuropsychological screening and assessment strategies in MS

  2007cited by this paper
• Validity of the Wisconsin Card Sorting and Delis–Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis

  2007cited by this paper
• How to detect cognitive dysfunction at early stages of multiple sclerosis?

  2006cited by this paper
• The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration.

  2006cited by this paper
• Predicting neuropsychological abnormalities in multiple sclerosis.

  2006cited by this paper
• Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)

  2006influential reference
• Interpreting patient/informant discrepancies of reported cognitive symptoms in MS

  2005cited by this paper
• Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change.

  2005cited by this paper
• Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers.

  2005cited by this paper
• Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

  2005cited by this paper
• Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire

  2003cited by this paper
• Cognitive dysfunction in multiple sclerosis: a review of recent developments.

  2003cited by this paper
• Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis

  2003cited by this paper
• Effects of Tyrosine, Phentermine, Caffeine d-amphetamine, and Placebo on Cognitive and Motor Performance Deficits During Sleep Deprivation

  2003cited by this paper
• Effects of methylphenidate on working memory in pigeons

  2003cited by this paper
• Cross-Sectional and Longitudinal Analysis

  2002cited by this paper
• Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years.

  2001cited by this paper
• Personality disorder in multiple sclerosis correlates with cognitive impairment.

  2001cited by this paper
• Diagnostic criteria for multiple sclerosis.

  2001cited by this paper
• Behavior Rating Inventory for Executive Function

  2000cited by this paper
• Effects of dextroamphetamine on cognitive performance and cortical activation.

  2000cited by this paper
• Acquisition and storage deficits in multiple sclerosis.

  1998cited by this paper
• Memory formation: the sequence of biochemical events in the hippocampus and its connection to activity in other brain structures.

  1997cited by this paper
• A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients

  1995cited by this paper
• A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

  1995cited by this paper
• Demographic, Clinical, and Cognitive Characteristics of Multiple Sclerosis Patients Who Continue to Work

  1995cited by this paper
• Amphetamine enhances memory retention and facilitates norepinephrine release from the hippocampus in rats.

  1995cited by this paper
• Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.

  1995cited by this paper
• Cognitive dysfunction in multiple sclerosis.

  1991cited by this paper
• The effects of d-amphetamine on arousal, cognition, and mood after prolonged total sleep deprivation.

  1989cited by this paper
• Brain dopamine and reward.

  1989cited by this paper
• The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.

  1989cited by this paper
• The neurochemistry and pharmacology of extinction behavior.

  1983cited by this paper
• Paced Auditory Serial-Addition Task: A Measure of Recovery from Concussion

  1977cited by this paper

• Does Dexamphetamine Cause Addiction? A Narrative Review

  2025cites this paper
• Assessment of the efficacy of lisdexamfetamine on fatigue in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled study.

  2025cites this paper
• Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review

  2023cites this paper
• Importance of Identifying Cognitive Impairment in Multiple Sclerosis

  2022cites this paper
• Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials

  2021cites this paper
• Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review

  2020cites this paper
• Pharmacotherapy in multiple sclerosis-induced cognitive impairment: A systematic review and meta-analysis.

  2020cites this paper
• Cognitive Functioning in Patients with Pediatric-Onset Multiple Sclerosis, an Updated Review and Future Focus

  2019cites this paper
• Improving Outcomes in Pediatric Multiple Sclerosis: Current and Emerging Treatments

  2019cites this paper
• Examining the effectiveness of acetylcholinesterase inhibitors and stimulant‐based medications for cognitive dysfunction in multiple sclerosis: A systematic review and meta‐analysis

  2018influential citation
• The neural correlates of effort-related and effort-unrelated fatigue in patients with multiple sclerosis

  2018cites this paper
• The neuropsychiatry of multiple sclerosis

  2018cites this paper
• Acute effects of lisdexamfetamine and D-amphetamine on social cognition and cognitive performance in a placebo-controlled study in healthy subjects

  2018cites this paper
• Advanced Symptom Management in Multiple Sclerosis.

  2018cites this paper
• Recommendations for cognitive screening and management in multiple sclerosis care

  2018cites this paper
• Treatment of neurocognitive symptoms in unipolar depression: A systematic review and future perspectives.

  2017cites this paper
• Information processing speed in multiple sclerosis: Past, present, and future

  2017cites this paper
• Cognitive impairment in multiple sclerosis – a review of current knowledge and recent research

  2017cites this paper
• Pathophysiology, assessment and management of multiple sclerosis fatigue: an update

  2017cites this paper
• Neuropsychology of Multiple Sclerosis: Looking Back and Moving Forward

  2017cites this paper
• The mediating role of processing speed in the relationship between depressive symptoms and cognitive function in multiple sclerosis

  2016cites this paper
• Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine

  2016cites this paper
• Fatigue and depression in multiple sclerosis: pharmacological and non‐pharmacological interventions

  2016cites this paper
• Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis

  2016cites this paper
• The Use of Amphetamines for Improving Cognitive Impairment in Patients with Multiple Sclerosis

  2016influential citation
• Effects of single dose mixed amphetamine salts - extended release on processing speed in multiple sclerosis: a double blind placebo controlled study

  2015cites this paper
• Multiple Sclerosis in the Elderly: Considerations in the Geriatric Population for Diagnosis and Management

  2015cites this paper
• The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders

  2014cites this paper
• Symptomatic treatment and management of multiple sclerosis.

  2014cites this paper
• Atomoxetine Effects on Executive Function as Measured by the BRIEF-A in Young Adults with ADHD: A Randomized, Double-Blind, Placebo-Controlled Study

  2014cites this paper
• Cognitive deficits in pediatric-onset multiple sclerosis: what does the future hold?

  2014cites this paper
• The use of stimulant medications for non-core aspects of ADHD and in other disorders.

  2014cites this paper
• Predictors of executive complaints and executive deficits in multiple sclerosis

  2014cites this paper
• Symptomatic Treatment in Multiple Sclerosis

  2013cites this paper
• Pharmacological treatment for memory disorder in multiple sclerosis.

  2013cites this paper
• Symptomatic therapy for multiple sclerosis

  2013cites this paper
• Pathophysiology, assessment and management of multiple sclerosis spasticity: an update

  2011cites this paper